Tongling Jieya Biologic Technology Co., Ltd. (SHE:301108)
China · Delayed Price · Currency is CNY 35.60
+1.71 (5.05%)
At close: Jul 31, 2026
SHE:301108 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 4,007 | 3,744 | 2,070 | 2,805 | 2,742 | 4,886 | |
Market Cap Growth | 33.08% | 80.83% | -26.20% | 2.31% | -43.89% | - |
Enterprise Value | 3,138 | 2,675 | 782 | 2,061 | 1,220 | 4,583 |
Last Close Price | 35.60 | 33.06 | 18.17 | 24.04 | 23.17 | 40.51 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 56.43 | 48.45 | 106.36 | 24.35 | 19.45 | 22.21 |
Forward PE | 16.56 | 16.26 | 14.31 | 19.19 | 15.76 | - |
PS Ratio | 4.77 | 4.85 | 3.78 | 4.51 | 4.11 | 4.96 |
PB Ratio | 2.11 | 1.99 | 1.13 | 1.51 | 1.54 | 2.89 |
P/TBV Ratio | 2.19 | 2.06 | 1.16 | 1.54 | 1.57 | 2.94 |
P/FCF Ratio | - | - | - | - | 10.19 | 38.30 |
P/OCF Ratio | 32.25 | 37.75 | 27.56 | 33.59 | 9.17 | 24.41 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 3.73 | 3.47 | 1.43 | 3.31 | 1.83 | 4.66 |
EV/EBITDA Ratio | 21.64 | 21.57 | 12.45 | 15.34 | 7.21 | 16.85 |
EV/EBIT Ratio | 33.09 | 32.32 | 42.01 | 20.08 | 9.06 | 18.84 |
EV/FCF Ratio | - | - | - | - | 4.53 | 35.92 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.05 | 0.02 | 0.01 | 0.01 | 0.02 | 0.02 |
Debt / EBITDA Ratio | 0.68 | 0.28 | 0.13 | 0.13 | 0.19 | 0.15 |
Debt / FCF Ratio | - | - | - | - | 0.12 | 0.31 |
Net Debt / Equity Ratio | -0.46 | -0.58 | -0.81 | -0.71 | -0.72 | -0.81 |
Net Debt / EBITDA Ratio | -6.42 | -8.87 | -23.61 | -9.84 | -7.53 | -5.06 |
Net Debt / FCF Ratio | 4.28 | 4.09 | 70.26 | 859.92 | -4.73 | -10.78 |
Asset Turnover | 0.38 | 0.35 | 0.26 | 0.30 | 0.32 | 0.68 |
Inventory Turnover | 7.56 | 6.97 | 6.14 | 6.65 | 4.47 | 5.48 |
Quick Ratio | 2.86 | 3.76 | 7.69 | 6.26 | 6.12 | 5.45 |
Current Ratio | 3.66 | 4.04 | 8.09 | 6.56 | 6.42 | 5.98 |
Return on Equity (ROE) | 4.16% | 4.17% | 1.04% | 6.30% | 8.12% | 20.61% |
Return on Assets (ROA) | 2.64% | 2.35% | 0.55% | 3.04% | 4.09% | 10.45% |
Return on Invested Capital (ROIC) | 9.37% | 13.16% | 3.23% | 16.70% | 28.44% | 87.07% |
Return on Capital Employed (ROCE) | 4.80% | 4.30% | 1.00% | 5.40% | 7.40% | 13.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 1.93% | 2.06% | 0.94% | 4.11% | 5.14% | 4.50% |
FCF Yield | -5.07% | -7.18% | -1.02% | -0.06% | 9.81% | 2.61% |
Dividend Yield | 0.84% | 0.76% | 0.55% | 1.07% | 1.54% | 1.32% |
Payout Ratio | 25.83% | 24.97% | 149.83% | 35.25% | 43.21% | 0.12% |
Buyback Yield / Dilution | -16.71% | 0.76% | -0.81% | -0.14% | -29.59% | -2.66% |
Total Shareholder Return | -15.87% | 1.51% | -0.27% | 0.93% | -28.05% | -1.34% |